Who are Entecavir dispersible tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Therapeutic entecavir, VALACYCLOVIR, cidofovir 1% topical ointment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/entecavir-dispersible-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Entecavir dispersible tablets — Competitive Intelligence Brief

Entecavir dispersible tablets (Entecavir dispersible tablets) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nucleoside analogue. Area: Infectious Disease.

phase 2 nucleoside analogue HBV DNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Entecavir dispersible tablets (Entecavir dispersible tablets) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Inhibits hepatitis B virus DNA polymerase

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Entecavir dispersible tablets TARGET	Entecavir dispersible tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 2	nucleoside analogue	HBV DNA polymerase
Therapeutic entecavir	Therapeutic entecavir	Taipei Veterans General Hospital, Taiwan	marketed	Nucleoside analog reverse transcriptase inhibitor (NRTI)	HBV DNA polymerase
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
cidofovir 1% topical ointment	cidofovir 1% topical ointment	Hospital Universitari Vall d'Hebron Research Institute	phase 3	Nucleoside analogue	DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nucleoside analogue class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Entecavir dispersible tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/entecavir-dispersible-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab